Dr. Benz graduated from Harvard Medical School in 1973 and received his training at Brigham and Women’s Hospital and the National Institutes of Health. He is president and CEO emeritus of Dana-Farber Cancer Institute, director emeritus and principal investigator of Dana-Farber/Harvard Cancer Center, and a member of the Governing Board of Dana-Farber/Children’s Cancer Center. He is also a clinical hematologist and an active NIH-funded investigator. He is the Richard and Susan Smith Distinguished Professor of Medicine, Professor of Pediatrics, Professor of Genetics, Harvard Medical School.

Dr. Benz is an internationally recognized hematologist and an active National Institutes of Health-funded Investigator. His laboratory studies focus on molecular regulation and functions of membrane cytoskeletal proteins that were originally discovered in the red blood cell. He has authored more than 300 peer reviewed articles, reviews, chapters, and abstracts. He is Co-editor of “Hematology: Principles and Practice,” which received the First Place Award for Textbooks from the British Medical Journal and of the “Oxford Textbook of Medicine,” for which he and his colleagues received the Royal Society of Authors Textbook Award. He is an Associate Editor of the New England Journal of Medicine.

Representative Publications:

Molecular genetics of the sickling syndromes: evolution of new strategies for improved diagnosis

Protein 4.1R Exon 16 3′ Splice Site Activation Requires Coordination among TIA1, Pcbp1, and RBM39 during Terminal Erythropoiesis

Newborn screening for α-thalassemia–keeping up with globalization

An erythroid differentiation-specific splicing switch in protein 4.1R mediated by the interaction of SF2/ASF with an exonic splicing enhancer

Learning about genomics and disease from the anucleate human red blood cell

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder